Back to All
Group

Webinar: The Value of Diagnostic Pre-Launch Planning for Targeted Therapies – Through the PD-L1 Lens

10 May, 2016

Are you planning to launch a diagnostic alongside a targeted therapy in the next 18-24 months. This webinar highlights Diaceutics' recent PD-L1 lost therapy opportunity assessment, which demonstrated that every $1 spent on smart diagnostic efficiency returns between $20-$40 in additional therapy revenues otherwise lost. It also highlights how effective diagnostic planning can maximize your therapy revenue opportunity. Listen to this webinar to learn:

  • that $1 spent on smart diagnostic efficiency returns between $20-$40 in additional therapy revenues otherwise lost; and
  • why ineffective diagnostic launch planning can lead to lost therapy revenue and how, with the proper planning tools, the maximum therapy opportunity can be achieved.

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world’s first Network solution for the development and commercialization of precision medicine diagnostics. 

Diaceutics has worked on every precision medicine brought to market and provides services to 36 of the world’s leading pharmaceutical companies. We have built the world’s largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries.